Verition Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.65M | Sell |
95,605
-14,905
| -13% | -$258K | 0.01% | 1553 |
|
|
2025
Q1 | $2.42M | Buy |
110,510
+60,100
| +119% | +$1.31M | 0.01% | 1126 |
|
|
2024
Q4 | $1.61M | Buy |
+50,410
| New | +$1.61M | 0.01% | 1282 |
|
|
2023
Q3 | – | Sell |
-3,997
| Closed | -$364K | – | 1970 |
|
|
2023
Q2 | $364K | Buy |
3,997
+347
| +10% | +$31.6K | ﹤0.01% | 1220 |
|
|
2023
Q1 | $241K | Buy |
+3,650
| New | +$241K | ﹤0.01% | 1521 |
|
|
2022
Q3 | – | Sell |
-5,259
| Closed | -$238K | – | 2421 |
|
|
2022
Q2 | $238K | Sell |
5,259
-47,640
| -90% | -$2.16M | ﹤0.01% | 1769 |
|
|
2022
Q1 | $2.69M | Sell |
52,899
-31,594
| -37% | -$1.61M | 0.03% | 522 |
|
|
2021
Q4 | $4M | Buy |
+84,493
| New | +$4M | 0.03% | 338 |
|
|
2021
Q3 | – | Sell |
-19,477
| Closed | -$1.23M | – | 1621 |
|
|
2021
Q2 | $1.23M | Buy |
19,477
+5,375
| +38% | +$340K | 0.01% | 608 |
|
|
2021
Q1 | $605K | Buy |
+14,102
| New | +$605K | 0.01% | 672 |
|
|
2020
Q3 | – | Sell |
-99,045
| Closed | -$3.24M | – | 962 |
|
|
2020
Q2 | $3.24M | Buy |
99,045
+57,656
| +139% | +$1.88M | 0.11% | 119 |
|
|
2020
Q1 | $1.11M | Buy |
41,389
+18,506
| +81% | +$496K | 0.04% | 180 |
|
|
2019
Q4 | $701K | Buy |
+22,883
| New | +$701K | 0.01% | 460 |
|